End-of-therapy response and corresponding survival. ^Patients 2, 4, 7, 8, 11, 13, 15, and 16 had to omit nivolumab for at least 1 cycle due to irAE. ∗Patients 12 and 14 expressed cytototoxic markers (ie, granzyme and/or TIA). Patients 2, 4, 6, 8, 11, and 17 were EBV-associated as defined in Table 1. PD, progressive disease.